GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Synergy Pharmaceuticals Inc (SGYP) [hlAlert]

Rating:
Outperform
SGYP
up 56.02 %

Synergy Pharmaceuticals Inc (SGYP) rated Outperform by Credit Suisse

Posted on: Friday,  Jun 21, 2013  8:25 AM ET by Credit Suisse

Credit Suisse rated Outperform Synergy Pharmaceuticals Inc (NASDAQ: SGYP) on 06/21/2013, when the stock price was $4.73. Since
then, Synergy Pharmaceuticals Inc has gained 56.03% as of 01/05/2016's recent price of $7.38.
If you would have followed this Credit Suisse's recommendation on SGYP, you would have gained 56.02% of your investment in 928 days.

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company?s lead drug candidate is SP-304, a guanylyl cyclase C (GC-C) receptor agonist, to treat GI disorders, primarily chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C). SP-304 is an analog of uroguanylin, a natural GI hormone secreted in the gut, which is a key regulator of intestinal function. As of December 31, 2009, the Company was developing SP-304, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. SP-304 is an agonist of GC-C. In February, 2010, a Phase IIa 14-day, repeated-oral-dose trial of SP-304 in CC patients opened for enrollment and was actively recruiting patients.

Excellence in equity and fixed income research is a hallmark of Credit Suisse. Globally, our equity research analysts provide in-depth coverage of over 2,500 companies and engage in a knowledge-sharing, value added culture that has yielded the most insightful product for our customers and tremendous competitive results. Additionally, Credit Suisse's powerful macro-economic and debt strategy teams integrate the bank's comprehensive company research with keen market perspectives of the ever-shifting investment terrain.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/21/2013 8:25 AM Buy
None
4.73
as of 12/13/2013
1 Week down  -3.86 %
1 Month down  -1.16 %
3 Months down  -10.00 %
1 YTD down  -10.57 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy